Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Oncology

Journal Scan / Research · January 26, 2023

Carfilzomib, Lenalidomide, and Dexamethasone vs Lenalidomide Alone as Maintenance Therapy After Autologous SCT in Patients With Multiple Myeloma

The Lancet Oncology


Additional Info

Disclosure statements are available on the authors' profiles:

The Lancet Oncology
Carfilzomib, lenalidomide, and dexamethasone or lenalidomide alone as maintenance therapy after autologous stem-cell transplantation in patients with multiple myeloma (ATLAS): interim analysis of a randomised, open-label, phase 3 trial
Lancet Oncol 2023 Jan 12;[EPub Ahead of Print], D Dytfeld, T Wróbel, K Jamroziak, T Kubicki, P Robak, A Walter-Croneck, J Czyż, A Tyczyńska, A Druzd-Sitek, K Giannopoulos, A Nowicki, T Szczepaniak, A Łojko-Dankowska, M Matuszak, L Gil, B Puła, J Rybka, M Majcherek, L Usnarska-Zubkiewicz, Ł Szukalski, A Końska, JM Zaucha, J Walewski, D Mikulski, O Czabak, T Robak, OB Lahoud, JA Zonder, K Griffith, A Stefka, A Major, BA Derman, AJ Jakubowiak

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading